Holistic preferences for 1-year health profiles describing fluctuations in health: The case of chronic obstructive pulmonary disease

PharmacoEconomics

Volumn 27, Issue 6, 2009, Pages 465-477

  Rutten Van Mölken, Maureen P M H ^a   Hoogendoorn, Martine ^a   Lamers, Leida M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONTROLLED CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; FEMALE; HOLISTIC HEALTH; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 68349118965     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927060-00003     Document Type: Article

References (41)

1. Bleichrodt H, Pinto J. Conceptual foundations for health utility measurement. In: Jones A, editor. The Elgar Companion to Health Economics. Cheltenham: Edward Elgar Publishing Limited, 2006: 347-358
2. Johannesson M. The ranking properties of healthy-years equivalents and quality-adjusted life-years under certainty and uncertainty. Int J Technol Assess Health Care 1995; 11 (1): 40-48
3. Verschuuren M. In search of realistic QALYs for short-term pain: the standard QALY model versus holistic assessment of profiles. Chapter 2. In: Quality adjusted life years and trade off exercises: exploring methodology and validity. Ph.D thesis. Utrecht: Utrecht University, Medical Faculty, 2006 [online]. Available from URL: http://igiturarchive. library.uu.nl/dissertations/ 2006-0516-200032/title. pdf [Accessed 2007 Apr 15]
4. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 1989; 9 (2): 142-149
5. Johannesson M, Pliskin JS, Weinstein MC. Are healthyyears equivalents an improvement over quality-adjusted life years? Med Decis Making 1993; 13 (4): 281-286
6. Tsuchiya A, Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005; 25 (4): 460-467 (Pubitemid 41023173)
7. Bonsel G, Janssen M, Birnie E. Mild Diseases & Ailments Study (MIDAS). Ziektelastbepaling van 27 vermoedelijk 'lichte' ziekten ten behoeve van rationele beperking van het geneesmiddelenpakket: samenvatting. Amsterdam: Amsterdam Medical Centre, Department of Social Medicine, 2003
8. Brazier J, Dolan P, Karampela K, et al. Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. Health Econ 2006; 15 (6): 543-551 (Pubitemid 43933233)
9. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23 (6): 932-946 (Pubitemid 38807371)
10. GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute, 2005 [online]. Available from URL: http://www.goldcopd. com [Accessed 2006 Jul 6]
11. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004; 98 (2): 99-107 (Pubitemid 38181126)
12. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 41 Suppl.: 46-53s
13. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1418-1422
14. Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002; 121 (3): 688-696
15. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19 (6): 623-642 (Pubitemid 32531837)
16. Rutten-van Mölken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3 (7): 630-634 (Pubitemid 44411632)
17. Dolan P. Modeling valuations for the EuroQol health states. Med Care 1997; 35: 1095-1108 (Pubitemid 127453463)
18. Rutten-van Mölken MP, Oostenbrink JB, Tashkin DP, et al. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 2006; 130 (4): 1117-1128
19. O'Reilly JF,Williams AE, Rice L. Health status impairment and costs associated with COPD exacerbation managed in hospital. Int J Clin Pract 2007; 61 (7): 1112-1120 (Pubitemid 46934632)
20. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365 (9470): 1552-1560 (Pubitemid 40615404)
21. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19 (2): 209-216 (Pubitemid 34162819)
22. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19 (2): 217-224 (Pubitemid 34162820)
23. Streiner D, Norman G. Health measurement scales: a practical guide to their development and use. Oxford: Oxford University Press, 1989
24. Lamers LM, Stalmeier PF, Krabbe PF, et al. Inconsistencies in TTO and VAS values for EQ-5D health states. Med Decis Making 2006; 26 (2): 173-181
25. Efron B, Tibshirani R. Cross-validation and other estimates of prediction error. Chapter 17. An introduction to the bootstrap. New York: Chapman & Hall, 1993
26. Richardson J, Hall J, Salkeld G. The measurement of utility in multiphase health states. Int J Technol Assess Health Care 1996; 12 (1): 151-162 (Pubitemid 26098463)
27. Kuppermann M, Shiboski S, Feeny D, et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med Decis Making 1997; 17 (1): 42-55 (Pubitemid 27020138)
28. Lipscomb J. Time preference for health in cost-effectiveness analysis. Med Care 1989; 27 (3 Suppl.): S233-53
29. MacKeigan LD, O'Brien BJ, Oh PI. Holistic versus composite preferences for lifetime treatment sequences for type 2 diabetes. Med Decis Making 1999; 19 (2): 113-121
30. Chapman GB. Preferences for improving and declining sequences of health outcomes. J Behav DecMaking 2000; 13: 203-218
31. Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006; 15 (10): 1121-1132 (Pubitemid 44596379)
32. Borg S, Ericsson A, Wedzicha JA, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004; 7 (2): 153-167 (Pubitemid 38420728)
33. Oostenbrink JB, Rutten-van Molken MP, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8 (1): 32-46
34. Hoogendoorn M, Feenstra T, Hoogenveen R, et al. A health policy model for COPD: effects of smoking cessation. Rotterdam: iMTA, Erasmus MC, 2003 Nov
35. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23 (6): 619-637 (Pubitemid 40994129)
36. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116 (5): 325-331 (Pubitemid 38230292)
37. Pickard AS, Kohlmann T, Janssen MF, et al. Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D. Med Care 2007; 45 (9): 812-819
38. Miller G. The magic number seven, plus or minus two: some limits in our capacity for processing information. Psychol Rev 1956; 63 (2): 81-97
39. Greiner W, Weijnen T, Nieuwenhuizen M, et al. A European EQ-5D VAS valuation set. In: Brooks R, Rabin R, De Charro F, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrecht: Kluwer Academic, 2003: 143-165
40. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res 1998; 7 (8): 693-702 (Pubitemid 29089249)
41. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998; 114 (4): 998-1007 (Pubitemid 28495893)